APA

Fox E., Mosse' Y. P., Meany H. M., Gurney J. G., Khanna G., Jackson H. A., Gordon G., Shusterman S., Park J. R., Cohn S. L., Adamson P. C., London W. B., Maris J. M. & Balis F. M. (20140604). Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). : Pediatric blood & cancer.

Chicago

Fox Elizabeth, Mosse' Yael P, Meany Holly M, Gurney James G, Khanna Geetika, Jackson Hollie A, Gordon Gary, Shusterman Suzanne, Park Julie R, Cohn Susan L, Adamson Peter C, London Wendy B, Maris John M and Balis Frank M. 20140604. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). : Pediatric blood & cancer.

Harvard

Fox E., Mosse' Y. P., Meany H. M., Gurney J. G., Khanna G., Jackson H. A., Gordon G., Shusterman S., Park J. R., Cohn S. L., Adamson P. C., London W. B., Maris J. M. and Balis F. M. (20140604). Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). : Pediatric blood & cancer.

MLA

Fox Elizabeth, Mosse' Yael P, Meany Holly M, Gurney James G, Khanna Geetika, Jackson Hollie A, Gordon Gary, Shusterman Suzanne, Park Julie R, Cohn Susan L, Adamson Peter C, London Wendy B, Maris John M and Balis Frank M. Time to disease progression in children with relapsed or refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group (ANBL0621). : Pediatric blood & cancer. 20140604.